Clinical Experience with 212Pb-Compounds
Time: 2:00 pm
day: Day one Track B PM
Details:
- Common treatment emergent adverse events in NETs
- Renal Toxicity: How is it defined and what can we do about it?
- Phase 1 Study of 212Pb-DOTAM-GRPR1 in Adult Subjects with Recurrent or Metastatic GRPR-expressing Tumors
